Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 10.1% – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price was down 10.1% during mid-day trading on Friday . The company traded as low as $3.63 and last traded at $3.63. Approximately 1,146,264 shares traded hands during trading, a decline of 18% from the average daily volume of 1,391,843 shares. The stock had previously closed at $4.04.

Autolus Therapeutics Trading Down 7.7 %

The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The stock’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $4.01. The firm has a market capitalization of $992.52 million, a PE ratio of -3.22 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts expect that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in Autolus Therapeutics in the 3rd quarter worth about $1,082,000. Privium Fund Management B.V. boosted its stake in Autolus Therapeutics by 15.6% in the 3rd quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock worth $674,000 after purchasing an additional 25,000 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock valued at $139,000 after acquiring an additional 14,959 shares during the period. Exchange Traded Concepts LLC lifted its stake in Autolus Therapeutics by 9.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after acquiring an additional 3,740 shares during the period. Finally, Herbst Group LLC bought a new position in Autolus Therapeutics during the 3rd quarter valued at about $91,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.